Switch to:
Also traded in: Canada, Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 6.01
OTCPK:ACBFF's Cash-to-Debt is ranked higher than
61% of the 799 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.05 vs. OTCPK:ACBFF: 6.01 )
Ranked among companies with meaningful Cash-to-Debt only.
OTCPK:ACBFF' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.02  Med: No Debt Max: No Debt
Current: 6.01
Equity-to-Asset 0.82
OTCPK:ACBFF's Equity-to-Asset is ranked higher than
79% of the 731 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. OTCPK:ACBFF: 0.82 )
Ranked among companies with meaningful Equity-to-Asset only.
OTCPK:ACBFF' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.32  Med: 0.74 Max: 1
Current: 0.82
0.32
1
Debt-to-Equity 0.12
OTCPK:ACBFF's Debt-to-Equity is ranked higher than
72% of the 568 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.30 vs. OTCPK:ACBFF: 0.12 )
Ranked among companies with meaningful Debt-to-Equity only.
OTCPK:ACBFF' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.09  Med: 0.7 Max: 3.03
Current: 0.12
0.09
3.03
Piotroski F-Score: 3
Altman Z-Score: 17.34
Beneish M-Score: 85.34
WACC vs ROIC
1.82%
-34.28%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % -106.62
OTCPK:ACBFF's Operating Margin % is ranked lower than
87% of the 758 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.95 vs. OTCPK:ACBFF: -106.62 )
Ranked among companies with meaningful Operating Margin % only.
OTCPK:ACBFF' s Operating Margin % Range Over the Past 10 Years
Min: -340.38  Med: -329.71 Max: -319.04
Current: -106.62
-340.38
-319.04
Net Margin % -117.05
OTCPK:ACBFF's Net Margin % is ranked lower than
86% of the 759 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.06 vs. OTCPK:ACBFF: -117.05 )
Ranked among companies with meaningful Net Margin % only.
OTCPK:ACBFF' s Net Margin % Range Over the Past 10 Years
Min: -397.78  Med: -369.08 Max: -340.38
Current: -117.05
-397.78
-340.38
ROE % -26.49
OTCPK:ACBFF's ROE % is ranked lower than
82% of the 780 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.91 vs. OTCPK:ACBFF: -26.49 )
Ranked among companies with meaningful ROE % only.
OTCPK:ACBFF' s ROE % Range Over the Past 10 Years
Min: -339.81  Med: -22.02 Max: 0.23
Current: -26.49
-339.81
0.23
ROA % -19.89
OTCPK:ACBFF's ROA % is ranked lower than
82% of the 805 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.71 vs. OTCPK:ACBFF: -19.89 )
Ranked among companies with meaningful ROA % only.
OTCPK:ACBFF' s ROA % Range Over the Past 10 Years
Min: -100.09  Med: -21.61 Max: 0.22
Current: -19.89
-100.09
0.22
ROC (Joel Greenblatt) % -52.76
OTCPK:ACBFF's ROC (Joel Greenblatt) % is ranked lower than
80% of the 793 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.48 vs. OTCPK:ACBFF: -52.76 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
OTCPK:ACBFF' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -22066.67  Med: -448.19 Max: -41.56
Current: -52.76
-22066.67
-41.56
3-Year EBITDA Growth Rate 12.90
OTCPK:ACBFF's 3-Year EBITDA Growth Rate is ranked higher than
58% of the 601 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.90 vs. OTCPK:ACBFF: 12.90 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
OTCPK:ACBFF' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 5.9  Med: 44.2 Max: 102.7
Current: 12.9
5.9
102.7
3-Year EPS without NRI Growth Rate 26.00
OTCPK:ACBFF's 3-Year EPS without NRI Growth Rate is ranked higher than
76% of the 576 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.60 vs. OTCPK:ACBFF: 26.00 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
OTCPK:ACBFF' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: 26 Max: 81.7
Current: 26
0
81.7
GuruFocus has detected 5 Warning Signs with Aurora Cannabis Inc $OTCPK:ACBFF.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» OTCPK:ACBFF's 30-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with OTCPK:ACBFF

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325411    SIC: 3741
Compare:TSX:APH, TSX:LEAF, TSX:GUD, NAS:AQXP, TSXV:OGI, TSX:CMED, TSX:WEED, TSXV:HIP, TSXV:RX, TSX:CPH, NAS:ARLZ, TSXV:THCX, XCNQ:BCC, XCNQ:MDM, TSXV:MGW, TSX:NRI, XCNQ:IN, TSXV:WMD, XCNQ:ISOL, XCNQ:MJ » details
Traded in other countries:ACB.Canada, 21P.Germany,
Headquarter Location:Canada
Aurora Cannabis Inc is a medical marijuana company. The Company is engaged in producing and distributing medical marijuana pursuant to the Marijuana for Medical Purposes Regulations.

Prescient Mining Corp was incorporated on December 21, 2006, under the laws of the Business Corporations Act. The Company is engaged in the acquisition, exploration, and development of natural resource properties.

Top Ranked Articles about Aurora Cannabis Inc

OTC Markets Group Welcomes Aurora Cannabis to OTCQX

Ratios

vs
industry
vs
history
Forward PE Ratio 555.56
ACBFF's Forward PE Ratio is ranked lower than
76% of the 67 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 18.90 vs. ACBFF: 555.56 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PB Ratio 5.85
ACBFF's PB Ratio is ranked lower than
72% of the 751 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.80 vs. ACBFF: 5.85 )
Ranked among companies with meaningful PB Ratio only.
ACBFF' s PB Ratio Range Over the Past 10 Years
Min: 0.26  Med: 0.96 Max: 19.18
Current: 5.85
0.26
19.18
PS Ratio 47.41
ACBFF's PS Ratio is ranked lower than
92% of the 736 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.97 vs. ACBFF: 47.41 )
Ranked among companies with meaningful PS Ratio only.
ACBFF' s PS Ratio Range Over the Past 10 Years
Min: 7.5  Med: 27.5 Max: 295
Current: 47.41
7.5
295
EV-to-EBIT -78.88
ACBFF's EV-to-EBIT is ranked lower than
99.99% of the 559 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 20.11 vs. ACBFF: -78.88 )
Ranked among companies with meaningful EV-to-EBIT only.
ACBFF' s EV-to-EBIT Range Over the Past 10 Years
Min: -80.3  Med: 0.9 Max: 161.4
Current: -78.88
-80.3
161.4
EV-to-EBITDA -85.63
ACBFF's EV-to-EBITDA is ranked lower than
99.99% of the 587 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.50 vs. ACBFF: -85.63 )
Ranked among companies with meaningful EV-to-EBITDA only.
ACBFF' s EV-to-EBITDA Range Over the Past 10 Years
Min: -87.3  Med: 0.9 Max: 101.6
Current: -85.63
-87.3
101.6
EV-to-Revenue 67.57
ACBFF's EV-to-Revenue is ranked lower than
91% of the 755 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.22 vs. ACBFF: 67.57 )
Ranked among companies with meaningful EV-to-Revenue only.
ACBFF' s EV-to-Revenue Range Over the Past 10 Years
Min: -22.4  Med: -0.3 Max: 435.6
Current: 67.57
-22.4
435.6
Current Ratio 29.50
ACBFF's Current Ratio is ranked higher than
98% of the 782 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.40 vs. ACBFF: 29.50 )
Ranked among companies with meaningful Current Ratio only.
ACBFF' s Current Ratio Range Over the Past 10 Years
Min: 0.14  Med: 78.39 Max: 1754
Current: 29.5
0.14
1754
Quick Ratio 28.37
ACBFF's Quick Ratio is ranked higher than
98% of the 782 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.82 vs. ACBFF: 28.37 )
Ranked among companies with meaningful Quick Ratio only.
ACBFF' s Quick Ratio Range Over the Past 10 Years
Min: 0.11  Med: 78.39 Max: 1754
Current: 28.37
0.11
1754
Days Sales Outstanding 28.65
ACBFF's Days Sales Outstanding is ranked higher than
86% of the 651 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 74.70 vs. ACBFF: 28.65 )
Ranked among companies with meaningful Days Sales Outstanding only.
ACBFF' s Days Sales Outstanding Range Over the Past 10 Years
Min: 21.31  Med: 210.71 Max: 400.1
Current: 28.65
21.31
400.1

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -103.70
ACBFF's 3-Year Average Share Buyback Ratio is ranked lower than
98% of the 473 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.10 vs. ACBFF: -103.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ACBFF' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -103.7  Med: -17.2 Max: -0.3
Current: -103.7
-103.7
-0.3

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 11.96
ACBFF's Price-to-Net-Cash is ranked higher than
56% of the 239 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 11.21 vs. ACBFF: 11.96 )
Ranked among companies with meaningful Price-to-Net-Cash only.
ACBFF' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0.75  Med: 1.13 Max: 45.67
Current: 11.96
0.75
45.67
Price-to-Net-Current-Asset-Value 9.82
ACBFF's Price-to-Net-Current-Asset-Value is ranked lower than
53% of the 512 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.25 vs. ACBFF: 9.82 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
ACBFF' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.75  Med: 1.13 Max: 27.4
Current: 9.82
0.75
27.4
Price-to-Tangible-Book 6.77
ACBFF's Price-to-Tangible-Book is ranked lower than
67% of the 690 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.51 vs. ACBFF: 6.77 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ACBFF' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.35  Med: 1.24 Max: 15.6
Current: 6.77
0.35
15.6
Price-to-Intrinsic-Value-Projected-FCF 16.18
ACBFF's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
88% of the 328 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.31 vs. ACBFF: 16.18 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
ACBFF' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 2.33  Med: 3.5 Max: 57.5
Current: 16.18
2.33
57.5
Price-to-Median-PS-Value 1.72
ACBFF's Price-to-Median-PS-Value is ranked higher than
66% of the 712 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.09 vs. ACBFF: 1.72 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ACBFF' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.36  Med: 1.64 Max: 9
Current: 1.72
0.36
9
Earnings Yield (Greenblatt) % -1.27
ACBFF's Earnings Yield (Greenblatt) % is ranked lower than
74% of the 805 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. ACBFF: -1.27 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ACBFF' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -137.2  Med: 15.2 Max: 1180
Current: -1.27
-137.2
1180

More Statistics

Revenue (TTM) (Mil) $10.07
EPS (TTM) $ -0.05
Short Percentage of Float0.00%
52-Week Range $0.00 - 2.96
Shares Outstanding (Mil)358.35

Analyst Estimate

Jun17 Jun18 Jun19 Jun20
Revenue (Mil $) 16 71 175 350
EPS ($) -0.02 0.03 0.12 0.25
EPS without NRI ($) -0.02 0.03 0.12 0.25
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for OTCPK:ACBFF

Headlines

Articles On GuruFocus.com
OTC Markets Group Welcomes Aurora Cannabis to OTCQX Mar 31 2017 
RETRANSMISSION: Aurora Cannabis Exceeds 3,000 Active Registered Patients in Five Months May 31 2016 
Aurora Cannabis Exceeds 3,000 Active Registered Patients in Five Months May 30 2016 
Aurora Announces Q3 2016 Results May 30 2016 
Michael Singer Joins Aurora Board as Independent Director May 24 2016 
Aurora Cannabis Surpasses 2,000 Registered Patients in Four Months May 09 2016 
Aurora Cannabis Provides Operational Update Apr 01 2016 
Aurora Receives License to Extract Cannabis Oils Feb 17 2016 
Aurora Continues Accelerated Growth Feb 02 2016 
Aurora Announces Completion of Pre-License Assessments by Health Canada, Receipt of Production Licen Oct 01 2015 

More From Other Websites
Aurora Begins Supplying German Medical Cannabis Market Sep 19 2017
Aurora Cannabis and Hempco Complete Investment Agreement Sep 18 2017
Operational Update: Aurora Cannabis Surpasses 19,000 Patients; Record Monthly Revenue, Shipments,... Aug 31 2017
This Marijuana Stock Skyrocketed Last Week, While 3 Others Plunged Aug 09 2017
Aurora Cannabis Expands Leadership Team, Appointing New Vice Presidents and Officers Aug 08 2017
Why the 3 Hottest Marijuana Stocks of the Summer Could Get Even Hotter Aug 06 2017
Radient Technologies Announces Conversion of Aurora Cannabis Debenture Jul 31 2017
Aurora and Hempco Agree on Terms for Strategic Investment Jul 31 2017
The Only 2 Marijuana Stocks to Report a Profit in Their Latest Quarterly Results Jul 28 2017
The 3 Hottest Marijuana Stocks Right Now Jul 26 2017
The Average Marijuana Stock Is Up 332% Over the Past Year Jul 24 2017
MEDIA ADVISORY: Aurora Cannabis Rings the Bell to Open the Market on First Day Trading on Toronto... Jul 24 2017
3 Things You Really Need to Know About Marijuana Stock MedReleaf Jul 21 2017
Aurora Cannabis Starts Trading on Toronto Stock Exchange Jul 21 2017
These 4 Marijuana Stocks All Jumped at Least 10% Last Week Jul 19 2017
Aurora and Cann Group Execute Technical Services Agreement Jul 18 2017
Bad News for Canadian Marijuana Stocks: Say Hello to Your New Competition Jul 17 2017
Aurora Cannabis Hosts Australian Delegation Led by the Honourable Jaala Pulford, Minister of... Jul 13 2017
Aurora Cannabis Passes First Stage of German Domestic Production Tender Application Process Jul 12 2017
3 Things Investors Really Need to Know About Marijuana Stock Canopy Growth Corporation Jul 11 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}